33 results about "Acute thrombosis" patented technology

An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a first diameter to a second diameter. A plurality of different beneficial agents may be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different agents may also be used to address different diseases from the same drug delivery device. In addition, anti-thrombotic agents may be affixed to at least a portion of the surfaces of the medical device for the prevention of sub-acute thrombosis. To ensure that the different agents remain affixed to the device as well as to each other, primer layers may be utilized.

An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a first diameter to a second diameter. A plurality of different beneficial agents may be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different agents may also be used to address different diseases from the same drug delivery device. In addition, anti-thrombotic agents may be affixed to at least a portion of the surfaces of the medical device for the prevention of sub-acute thrombosis. To ensure that the different agents remain affixed to the device as well as to each other, masking and de-masking processes may be utilized.

The invention provides a ticagrelor sustained-release tablet system and a preparation method of the ticagrelor sustained-release tablet system. The preparation method comprises the following steps of: firstly uniformly mixing 10-60% of ticagrelor, 5-60% of a filler and 5-60% of high molecular polymer in percentage by weight, adding a granulating solution to granulate; fully drying the obtained granules at a temperature of 50-60 DEG C, uniformly mixing the sieved granules with 0.25-10% of a lubricant and / or 0-10% of a flow aid, carrying out tabletting to obtain the ticagrelor matrix type sustained-release tablets, wherein the granulating solution is preferably water, an alcohol-water solution or absolute ethyl alcohol; the granule size of the ticagrelor is below 100 micrometers; and the content of the ticagrelor is 50-300mg in the preparation process. The ticagrelor matrix type sustained-release tablet system provided by the invention has the advantages that a patient can take the ticagrelor once a day to ensure that the drug dependence of the patient can be improved and the risk of myocardial infarction or apoplexy caused by acute thrombosis due to a dose of the ticagrelor missing of the patient is reduced.

The present invention relates to a combination of agents, including an anti-proliferative agent, an anti-inflammatory agent, an anti-growth factor, and an extracellular matrix (ECM) molecule coated on a stent to prevent acute and subacute thrombosis, enhance endothelial in-growth, and prevent neointimal hyperplasia, and / or suppress neovascularization, and thereby reduce restenosis rates for drug eluting stents. The present invention also relates to methods of using such multiple drug eluting stents for the treatment of heart disease and other vascular conditions.

The invention relates to a formulation of ticagrelor or a pharmaceutically acceptable salt thereof. In particular, the present invention relates to an improved formulation of ticagrelor, or a pharmaceutically acceptable salt thereof, administered once a day. The present invention can achieve a plasma concentration of ticagrelor of greater than about 0.2 [mu] g / mL within 2 hours in a subject; and aplasma concentration of ticagrelor of greater than about 0.2 [mu] g / mL can still be achieved after administration in a subject for 12 hours; and generating a maximum plasma concentration (Cmax) of ticagrelor or a pharmaceutically acceptable salt thereof between about 0.2 [mu] g / mL and about 0.8 [mu] g / mL in the subject. According to the preparation of the ticagrelor or the medicinal salt thereof,the administration frequency can be reduced, so that the administration compliance of a patient can be improved, and the risk of myocardial infarction or stroke caused by acute thrombosis due to missing administration of the ticagrelor by the patient is reduced.

The invention discloses a dipyridamole-loaded polyurethane anticoagulative material and a preparation process thereof. The material adopts a core-shell structure, the inner layer is a dipyridamole loaded layer, and the outer layer is a polyurethane main body layer. When the material is used as an artificial blood vessel to be transplanted, the dipyridamole can be slowly released in a long term, adhesion, aggregation and activation of platelets on the surface of the artificial blood vessel are inhibited, the blood compatibility of the artificial blood vessel is improved, the acute thrombosis and intima proliferation can be effectively avoided, and the transplanting success rate of the artificial blood vessel can be effectively improved.

An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a first diameter to a second diameter. A plurality of different beneficial agents may be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different agents may also be used to address different diseases from the same drug delivery device. In addition, anti-thrombotic agents may be affixed to at least a portion of the surfaces of the medical device for the prevention of sub-acute thrombosis. Primer layers may be used to ensure that the different agents remain affixed to the device as well as to each other.

The invention provides a medicine elution balloon. The surface of the balloon is coated with medicine; the medicine coating comprises a medicine capable of inhibiting endotheliosis and a first medicine in a mass ratio of (0.5 to 20): 1, and the first medicine is one or more of hirudin and hirudin derivatives. Two or more components are smeared on the medicine elution balloon, by utilizing the traditional Chinese medicine compatibility toxicity reducing and efficacy enhancing theory, the blood vessel smooth muscle cell proliferation can be maximally inhibited, the blood vessel endothelialization process is minimally inhibited, and a purpose of effectively treating stenotic pathologic change as well as acute thrombosis, sub-acute thrombosis or late stent thrombosis can be finally achieved.